Since mitochondrial dysfunction is a key contributor to the pathogenesis of both diabetic nephropathy and cardiomyopathy, the ability of SGLT2 inhibitors to modulate mitochondrial function could be a critical mechanism underlying their protective effects [85]. This evidence concerns the gene SLC5A2 and diabetic kidney disease.